Vimarsana
Biggest News Aggregation in the World

Visium Spatial Gene Expression News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Visium Spatial Gene Expression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Visium Spatial Gene Expression Today - Breaking & Trending Today

10x Genomics, Inc. Share Price Target '$58.50', now 21.7% Upside Potential - Vimarsana News

10x Genomics, Inc. Share Price Target '$58.50', now 21.7% Upside Potential

Published: February 16, 2024

10x Genomics, Inc. Share Price Target '$58.50', now 21.7% Upside Potential

Source: directorstalkinterviews.com
Related Topics:
Genomics IncChromiumx SeriesChromium ConnectChromium ControllerChromium Single Cell Gene ExpressionChromium Single Cell Gene Expression FlexChromium Single Cell Immune ProfilingChromium Single CellChromium Single Cell MultiomeGene ExpressionVisium Spatial Gene ExpressionVisium Spatial ProteogenomicsXenium In Situ Gene
10x Genomics, Inc. - Consensus 'buy' rating and 21.0% Upside Potential - Vimarsana News

10x Genomics, Inc. - Consensus 'buy' rating and 21.0% Upside Potential

Published: December 7, 2023

10x Genomics, Inc. - Consensus 'buy' rating and 21.0% Upside Potential

Source: directorstalkinterviews.com
Related Topics:
Paylocity Holding CorporationGenomics IncChromiumx SeriesChromium ConnectChromium ControllerChromium Single Cell Gene ExpressionChromium Single Cell Gene Expression FlexChromium Single Cell Immune ProfilingChromium Single CellChromium Single Cell MultiomeGene ExpressionVisium Spatial Gene ExpressionVisium Spatial ProteogenomicsXenium In Situ Gene
10x Genomics, Inc. - Consensus 'buy' rating and 71.0% Upside Potential - Vimarsana News

10x Genomics, Inc. - Consensus 'buy' rating and 71.0% Upside Potential

Published: November 1, 2023

10x Genomics, Inc. - Consensus 'buy' rating and 71.0% Upside Potential

Source: directorstalkinterviews.com
Related Topics:
Genomics IncChromiumx SeriesChromium ConnectChromium ControllerChromium Single Cell Gene ExpressionChromium Single Cell Gene Expression FlexChromium Single Cell Immune ProfilingChromium Single CellChromium Single Cell MultiomeGene ExpressionVisium Spatial Gene ExpressionVisium Spatial ProteogenomicsXenium In Situ Gene
10x Genomics, Inc. - Consensus 'buy' rating and 12.7% Upside Potential - Vimarsana News

10x Genomics, Inc. - Consensus 'buy' rating and 12.7% Upside Potential

Published: August 9, 2023

10x Genomics, Inc. - Consensus 'buy' rating and 12.7% Upside Potential

Source: directorstalkinterviews.com
Related Topics:
Genomics IncPaylocity Holding CorporationChromiumx SeriesChromium ConnectChromium ControllerChromium Single Cell Gene ExpressionChromium Single Cell Gene Expression FlexChromium Single Cell Immune ProfilingChromium Single CellChromium Single Cell MultiomeGene ExpressionVisium Spatial Gene ExpressionVisium Spatial ProteogenomicsXenium In Situ Gene
Top 10 Spatial Biology Companies - Vimarsana News

Top 10 Spatial Biology Companies

Published: March 2, 2023

New technologies, recognition, and the thrill of discovery propel the field’s largest public and private companies (plus eight up-and-comers).

Source: genengnews.com
Related Topics:
United StatesHarvard UniversityRnascope HiplexIonpath MibiscopeAkoya PhenocyclerArutha KulasingheJoe BeechemVeranome BiosystemsSusan TousiAkoya Bioscience PhenoimagerAkoya PhenoimagerAkoya BiosciencesYoni BockUs Centers For DiseaseStockholm Royal Institute Of TechnologyCold Spring Harbor LaboratoryBrain Initiative Cell Census NetworkResearch AndEdenroc SciencesJefferson HealthUniversity Of PittsburghAustralian Cancer Research FoundationVizgen Data Release ProgramCandor TechnologyUs District Court